Overview
Hemas is a diversified group centred on healthcare and consumer businesses, with additional exposure to hospitality, travel, mobility and logistics. Healthcare represents 62% of reported segment revenue, making pharmaceutical distribution, manufacturing and hospitals the main operating context for the group.
The most important recent change is its first overseas acquisition: the group entered Kenya through a majority stake in Twiga Stationers and Printers, giving Atlas Axillia a platform for East African consumer expansion. The strategic rationale is clear, but the current filings do not yet show the acquisition's financial contribution.
Price performance
HHL gained 0.6% over one week and 0.3% over one month, while the ASPI gained approximately 0.0% and 1.0% over those windows. Over six months HHL fell 7.4%, compared with a 9.5% ASPI decline, and over one year it rose 1.9% against the index's 8.0% gain.
The closing price was LKR 31.50 as at 19 August 2026. It sat 14.0% below the 52-week high and at 40.0% of its 52-week range, closer to the low than the high. Trading has also quietened: 20-day volume was 35.4% below the 60-day average, while 60-day annualised volatility was 26.6% below the company's own one-year level.
Valuation
HHL trades at 10.88 times earnings and 1.69 times book value, against sector medians of 14.07 and 1.23 respectively. This places its P/E at the 31st sector percentile but its P/B at the 70th percentile. The higher book multiple is consistent with a 15.7% annual return on equity rather than being an isolated valuation premium.
The 3.2% dividend yield is at the 60th sector percentile. The payout has been rising across the latest recorded years, from LKR 0.68 per share in FY2024 to LKR 0.90 in FY2025 and LKR 1.00 in FY2026. Dividend cover is 2.9 times, so the yield is supported by a payout that has increased rather than been repeatedly cut.
News and sentiment
Coverage was unusually heavy, with six articles in the last 30 days against Hemas's own monthly baseline of 2.7. Across the 90-day window, 14 of 21 material articles were positive, six negative and one neutral.
The Kenya acquisition generated positive coverage, while two 7 August reports highlighted the June quarter's earnings decline and management's margin-recovery actions. The final FY2026 dividend of LKR 0.75 per share went ex on 30 June 2026. The 1:5 share subdivision went ex on 7 May 2025, so historical per-share figures must be read on the restated share basis.
Financials
The June 2026 quarter was broadly flat on revenue, which grew 0.9% year-on-year to LKR 28.77 billion, but operating profit fell LKR 437 million and net profit fell LKR 197 million. Gross margin widened from 30.1% to 30.4%, while operating margin narrowed from 7.2% to 5.7% and net margin from 4.4% to 3.7%.
June is structurally Hemas's weakest quarter for operating margin, averaging 6.4% across six observations versus 12.1% in December. The latest 5.7% operating margin ranked 5 of 7 comparable June quarters, while gross margin ranked 2 of 7 and net margin 5 of 7. The operating result therefore reflects both the normal June pattern and a weaker like-for-like operating position than the best recent June outcomes.
The twelve months to June 2026 produced revenue of LKR 127.61 billion, up 5.4%, with operating and net margins of 10.7% and 7.1%. Latest quarter profit also faced LKR 569 million of finance costs, tax, associates and foreign-exchange effects below operating profit. Equity attributable to owners was LKR 55.80 billion, and the current share count was 2.996 billion following the 1:5 subdivision; per-share comparisons before that action are mechanically distorted.
Risks
The main financial risk is that weaker operating earnings are not matched by cash generation. Annual cash conversion was 0.83 times in March 2026, below one, meaning operating profit did not fully arrive as operating cash, while free cash flow was LKR 9.40 billion.
Balance-sheet leverage is currently modest, with total debt of LKR 6.15 billion and gearing of 10.8% of owners' equity. Interest cover was strong at 13.79 times and the current ratio was 1.72, but the June earnings decline shows that margin pressure can emerge even without heavy leverage. Minority shareholders received 4.0% of group profit, a material enough share to keep group net profit distinct from earnings attributable to HHL owners.
For the operating businesses, healthcare is the dominant exposure at 62% of segment revenue, while consumer retail accounts for 38%. Sector reporting points to continued pharmaceutical input and regulatory concerns, and consumer reporting points to inflation and energy-cost pressure. These are relevant exposures, not company-specific news.
Outlook
As at 19 August 2026, the next identifiable event is the filing for the quarter ending 30 September 2026. Based on exchange timing, it is expected from 7 November 2026 to 5 January 2027, and will supersede the June figures used here. That filing will provide the first reported evidence of whether the Kenya acquisition has begun contributing and whether the June cost pressure has translated into a broader earnings pattern.
As at 19 August 2026, Sri Lankan money-market and Treasury bill rates were moving lower, while energy costs and inflation remained pressure points. The rate backdrop could reduce financing pressure, but the consumer and healthcare exposures leave input-cost and pricing execution important. The available data cannot yet quantify the acquisition's returns, integration costs or effect on group margins.